Subgroup variables | No of studies | No of patients | Effects model | HR (95% CI) | P value | Heterogeneity I2 (%) Ph | |
RFS | |||||||
Total | 8 | 2307 | FEM | 2.02 (1.66 to 2.47) | <0.001 | 0 | 0.881 |
Country | |||||||
China | 7 | 2262 | FEM | 2.01 (1.63 to 2.48) | <0.001 | 0 | 0.808 |
Turkey | 1 | 45 | – | 2.14 (1.14 to 4.03) | 0.018 | – | – |
Sample size | |||||||
≤300 | 4 | 787 | FEM | 2.14 (1.64 to 2.79) | <0.001 | 0 | 0.926 |
>300 | 4 | 1520 | FEM | 1.88 (1.38 to 2.55) | <0.001 | 0 | 0.537 |
Treatment | |||||||
Surgical resection | 7 | 2027 | FEM | 2.16 (1.71 to 2.72) | <0.001 | 0 | 0.926 |
Surgical resection+TKIs | 1 | 280 | – | 1.69 (1.14 to 2.50) | 0.009 | – | – |
Cut-off value | |||||||
≤47.45 | 4 | 1096 | FEM | 1.88 (1.47 to 2.40) | <0.001 | 0 | 0.917 |
>47.45 | 4 | 1211 | FEM | 2.35 (1.66 to 3.33) | <0.001 | 0 | 0.696 |
Cut-off determination | |||||||
ROC curve | 7 | 1950 | FEM | 1.94 (1.56 to 2.43) | <0.001 | 0 | 0.882 |
Median value | 1 | 357 | – | 2.40 (1.52 to 3.80) | <0.001 | – | – |
Survival analysis type | |||||||
MVA | 7 | 1950 | FEM | 1.94 (1.56 to 2.43) | <0.001 | 0 | 0.882 |
UVA | 1 | 357 | – | 2.40 (1.52 to 3.80) | <0.001 | – | – |
Overall survival | |||||||
Total | 1 | 45 | – | 4.35 (1.25 to 16.83) | 0.033 | – | – |
FEM, fixed-effects model; MVA, multivariate analysis; OS, overall survival; PNI, Prognostic Nutritional Index; RFS, recurrence-free survival; ROC, receiver operating characteristic; TKIs, tyrosine kinase inhibitors; UVA, univariate analysis.